News
RIGL
42.55
-2.77%
-1.21
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
NASDAQ · 5d ago
Rigel Pharmaceuticals grants 13,375 inducement RSUs to six new hires
PUBT · 5d ago
RIGEL PHARMACEUTICALS, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Weekly Report: what happened at RIGL last week (0629-0703)?
Weekly Report · 6d ago
Rigel Appoints Alison Hannah as New Chief Medical Officer
TipRanks · 07/01 20:34
RIGEL PHARMACEUTICALS - APPOINTS ALISON L. HANNAH AS EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER EFFECTIVE JULY 1, 2026 - SEC FILING
Reuters · 07/01 20:12
Rigel Appoints Alison Hannah As CMO To Succeed Lisa Rojkjaer
NASDAQ · 07/01 15:26
Rigel CMO Lisa Rojkjaer Retires, Alison Hannah Appointed As New CMO
NASDAQ · 07/01 13:20
Rigel appoints Alison L. Hannah as chief medical officer
Seeking Alpha · 07/01 12:58
Rigel appoints Alison Hannah as Chief Medical Officer and Vice President
TipRanks · 07/01 12:10
Rigel names board member Alison Hannah chief medical officer, replacing Lisa Rojkjaer
PUBT · 07/01 12:06
RIGEL APPOINTS BOARD MEMBER ALISON L. HANNAH, M.D. AS CHIEF MEDICAL OFFICER
Reuters · 07/01 12:05
Press Release: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Dow Jones · 07/01 12:05
Weekly Report: what happened at RIGL last week (0622-0626)?
Weekly Report · 06/29 10:18
Weekly Report: what happened at RIGL last week (0615-0619)?
Weekly Report · 06/22 10:27
A Look At The Transformation Around Rigel Pharmaceuticals
Seeking Alpha · 06/20 11:44
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha · 06/18 11:43
Rigel Expands Oncology Portfolio with VEPPANU Global Rights
TipRanks · 06/17 21:24
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
PUBT · 06/17 20:06
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 06/17 11:02
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.